President Donald Trump tells reporters that he is taking zinc and hydroxychloroquine during a meeting with restaurant industry executives about the coronavirus response, in the State Dining Room of the White House, Monday, May 18, 2020, in Washington. (AP Photo/Evan Vucci)
By Zeke Miller and Darlene Superville
Updated 6:10 pm ET
President Donald Trump said Monday that he is taking a malaria drug to protect against the new coronavirus, despite warnings from his own government that it should only be administered for COVID-19 in a hospital or research setting due to potentially fatal side effects.
Trump told reporters he has been taking the drug, hydroxychloroquine, and a zinc supplement daily “for about a week and a half now.” Trump spent weeks pushing the drug as a potential cure or prophylaxis for COVID-19 against the cautionary advice of many of his administration's top medical professionals. The drug has the potential to cause significant side effects in some patients and has not been shown to combat the new coronavirus.
Trump said his doctor did not recommend the drug to him, but he requested it from the White House physician.
"I started taking it, because I think it’s good," Trump said. "I’ve heard a lot of good stories.”
The Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings, due to sometimes fatal side effects. Regulators issued the alert for the drug, which can also be used to treat lupus and arthritis, after receiving reports of heart-rhythm problems, including deaths, from poison control centers and other health providers.
Trump dismissed reports of side effects, saying, “All I can tell you is, so far I seem to be OK.”
At least two White House staffers tested positive for COVID-19 earlier this month, sparking concerns about the steps taken by the administration to protect the president and sending Vice President Mike Pence and other officials into varying forms of self-isolation.
The White House has since mandated that those in the West Wing wear face coverings and has introduced daily testing for the virus for the president, vice president, and those they come in close contact with.
Trump last underwent an “interim” checkup in a November visit to Walter Reed National Military Medical Center that was not noted on his public schedule. His last complete physical took place in February 2019.
Trump has repeatedly pushed the use of the drug with or without the antibiotic azithromycin, but no large, rigorous studies have found them safe or effective for preventing or treating COVID-19.
Two large observational studies, each involving around 1,400 patients in New York, recently found no benefit from hydroxychloroquine. Two new ones published Thursday in the medical journal BMJ reached the same conclusion.
One, by French researchers, gave 84 hospitalized patients the drug and 97 others the usual care. There were no differences in the odds of death, need for intensive care or developing severe illness.
The other study from China was a stricter test: 150 adults hospitalized with mild or moderate illness were randomly assigned to get hydroxychloroquine or usual care. The drug made no difference in rates of clearing the virus or time to relief of symptoms, and they brought more side effects.
In April, the National Institutes of Health launched a study testing hydroxychloroquine versus a placebo drug in 500 hospitalized COVID-19 patients. Last week, NIH announced another study to see if hydroxychloroquine plus azithromycin can prevent hospitalization or death in people with mild to moderate illness. About 2,000 U.S. adults with confirmed coronavirus infections and symptoms such as fever, cough, or shortness of breath will get the drugs or placebo pills.
U.S. prescriptions for hydroxychloroquine surged roughly 80% in March to more than 830,000 compared with the same period in the prior year, according to data tracking firm IQVIA. That jump in prescribing came before the federal government accepted nearly 30 million doses of the drug donated to the strategic national stockpile by foreign drugmakers. Since then, millions of those tablets have been shipped to U.S. hospitals nationwide for use treating patients with COVID-19.
—-
AP medical writers Marilynn Marchione in Milwaukee and Matthew Perrone in Washington contributed to this report.
If some members of Congress have their way, there might finally be a 'TLDR' on sites' terms of service, introduced by the terms-of-service labeling, design, and readability act – or TLDR for short. With this act, users will actually understand what they're agreeing to or the many ways in which their data is being used before pressing 'accept.' J.D. sat down with co-sponsor of the bill and Senator Bill Cassidy, to discuss.
President Joe Biden's first year in office is wrapping up. What has he achieved, and what else remains on the table while the Democrats have control of Washington? Amid an ongoing pandemic and rising inflation, Biden's approval rating is at an all-time low and his party is plagued by infighting. Will he be able to continue pushing key parts of his agenda? Paul Glastris, former Bill Clinton speechwriter & Editor-in-chief of 'Washington Monthly,' joins Cheddar News' Closing Bell to discuss the president's achievements in his first year, where he's fallen short, and what he must do in order to get more of his agenda signed into law.
Tech giants Meta, Amazon, Alphabet, and Apple are faced with a bipartisan antitrust legislation effort underway in the Senate Judiciary Committee. The companies stand accused of promoting their own goods and services over smaller competitors on their platforms, holding too much monopolistic power via their app stores and services. Adam Kovacevich, founder and CEO of Chamber of Progress, a technology industry trade group, joined Cheddar to argue that the bills that are being debated currently could end up hurting consumers, rather than helping.
Concerns over inflation have become one of the biggest worries for executives. A survey from The Conference Board shows that more than 900 CEOs consider inflation a top tier concern, a major shift from last year's survey that had it as a low-level concern. Rebecca Ray, Executive Vice President, Human Capital, The Conference Board joined Cheddar's Opening Bell for more.
Jordan Zakarin, Media Producer at A More Perfect Union, joined Cheddar News to break down the latest from Colorado, where at least 8,700 Kroger employees walked off the job in demand of increased benefits and wages.
With the 2022 Winter Olympics in Beijing rapidly approaching, clouds of controversy continue to swirl around China's treatment of the Uyghur Muslim minority population, its surveillance state, and security for visiting athletes. Phelim Kine, China correspondent for Politico, joined Cheddar to break down the big storylines surrounding the Beijing Games and highlight what he saw as the complete disregard by top corporate sponsors like P&G, Airbnb, Intel, Visa, and Coca-Cola, for the controversies. "They spend $100 million for every Olympics that they sponsor, and they have frankly shown absolute willful indifference to any type of entreaty to essentially be more vocal about their concerns about human rights in China," he said. Kine also touched on the data privacy fears for athletes as visiting contingents are being told to carry burner phones to avoid security risks.
Texas's six-week abortion ban remains in effect after a federal appeals court ruling on Monday. The U.S. court of appeals for the fifth circuit temporarily transferred the case to the Texas Supreme Court, which is expected to leave the dispute in limbo for months to come. Katie Barlow, attorney and media editor of SCOTUSblog, joins Cheddar News to discuss.
Hugh Odom, founder and president of Vertical Consultants, shared his expertise on telecommunications with Cheddar on the safety issue raised about 5G deployment by airlines. The installation was partially delayed again on Tuesday as the airlines warned of potentially catastrophic delays in a letter to the Biden administration. Later, both Verizon and AT&T relented and put a pause on some of the implementations. "The first thing the Biden administration needs to do is get everybody in the room and say, look, aviation industry, identify the problem — wireless industry, come up with a solution," said Odom.
Dave Levinthal, deputy Washington Bureau chief at Insider, joins Cheddar News to discuss Gallup's new survey that reveals more Americans leaned Republican by the end of 2021.
